Pemvidutide
InvestigationalA dual GLP-1/glucagon receptor agonist developed by Altimmune showing 15.6% weight loss at 48 weeks with a high proportion of fat mass lost. Phase 2 trials completed for obesity (MOMENTUM) and MASH (IMPACT), with the IMPACT trial meeting its MASH-resolution primary endpoint (52% at 1.8 mg vs 20% placebo at 24 weeks). FDA Fast Track designation for MASH.
ALT-801 · GLP-1/Glucagon Dual Agonist
12 human studies
- Preclinical
- 29%
- Clinical
- 43%
Based on 28 cited sources
clinically demonstrated · moderate confidence
Demonstrated effect magnitude — not a recommendation or safety claim.
Research Depth 88: multiple double-blind placebo-controlled Phase 2b RCTs — IMPACT MASH (41237796, Lancet, n=212), MASLD 12-wk (39002641, J Hepatol, n=94) and 24-wk extension (41113119, JHEP Rep, n=64), plus MOMENTUM obesity — now topped by a GRADE-assessed meta-analysis of pemvidutide RCTs (41879841); total human N in the 300-1,000 band; direct population/route/outcome match; moderate pemvidutide-specific preclinical foundation (1E). 1B held mid-band (22) because the meta-analysis is single/recent and the fibrosis-improvement co-primary was not met at 24 wk. Mechanism 93: GLP-1R + GCGR are validated targets with functional and loss-of-function confirmation for the class (Finan triagonist KO/blockade 25485909), full target-to-effect pathway, and monotonic human dose-response (1.2/1.8/2.4 mg) plus in-vivo BAT thermogenesis (24917578). Plausibility 88: near-full mechanism->surrogate (liver fat, weight)->clinical (MASH resolution) chain, fully coherent with hepatic/ metabolic biology, multiple same-class analogues (survodutide, tirzepatide, retatrutide); minor deduction as fibrosis/hard outcomes not yet met and the claim spans several metabolic systems. Global Coverage 49: pivotal trials are Altimmune-sponsored (single sponsor) at US/Australia sites, but an independent meta-analysis and multi-country reviews exist; ~12 pemvidutide-specific studies; FDA Fast Track + trial registration (4D=5, not yet approved). Community Experience 32: niche, recent investigational use only, limited but broadly consistent reports, no recurring adverse signal. Effectiveness basis clinical (moderate): MOMENTUM 15.6% vs 2.3% placebo weight loss and IMPACT ~52-58% vs 20% placebo MASH resolution far exceed their MCIDs (large effect), but evidence is Phase 2b, single-sponsor, with the fibrosis co-primary missed at 24 wk and no head-to-head vs resmetirom.
The mechanisms of pemvidutide are well-characterized through Phase 2b clinical trials and extensive preclinical research on GLP-1/glucagon dual agonism.
How It Works (Simplified)
Pemvidutide activates TWO hormone receptors simultaneously for enhanced metabolic effects:
GLP-1 receptor activation in the brain signals satiety, reducing hunger and caloric intake naturally.
Glucagon receptor activation directly tells liver cells to oxidize fat, reducing steatosis and improving MASH.
Glucagon increases energy expenditure and thermogenesis, burning more calories at rest.
Balanced dual agonism preferentially targets fat stores, preserving 78% fat mass loss vs typical 65-70%.
Key Research: MOMENTUM (NCT05295875) and IMPACT (NCT05989711) Phase 2 trials demonstrated consistent efficacy. [Altimmune 2024]
Important Limitations
- Phase 2b data only; Phase 3 confirmatory trials pending
- No head-to-head comparisons with approved agents
- Type 2 diabetes population not yet studied
- Long-term safety and durability beyond 48 weeks unknown
- All trials sponsored by single company (Altimmune)
Titration phase beginning at 0.6mg weekly. Initial appetite suppression and satiety effects. Common GI side effects (nausea, diarrhea) typically most pronounced during this period but improve with continued use.
NCT05295875Dose escalation to maintenance dose (1.8-2.4mg). Progressive weight loss averaging 1-2% body weight per month. Liver fat reduction begins. GI tolerability improves.
NCT05295875Sustained weight loss reaching approximately 10% at 24 weeks with 1.8mg dose. Significant improvements in liver enzymes. Metabolic parameters (lipids, blood pressure) show measurable improvement.
NCT05295875Continued weight loss to 15.6% at 48 weeks in the obesity trial. In the separate IMPACT MASH trial, MASH resolution without fibrosis worsening was observed in 52% of patients at 1.8 mg (vs 20% placebo) by the 24-week biopsy; the co-primary fibrosis-improvement endpoint was not met at 24 weeks. Weight loss trajectory not yet plateaued, suggesting further benefit with extended treatment.
NCT05989711Research-based observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Good Signs (5 indicators)
Warning Signs (3 indicators)
Bad Signs (5 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
BPC-157
CompatibleDifferent mechanisms of action. BPC-157 focuses on tissue repair while pemvidutide targets metabolic pathways. No known contraindications.
TB-500
CompatibleNon-overlapping mechanisms. TB-500 targets tissue repair and cell migration while pemvidutide modulates metabolic function. No interaction data available.
Semaglutide
CautionBoth target GLP-1 receptors. Co-administration would result in overlapping mechanisms with potential for increased GI side effects. Not recommended to combine.
Tirzepatide
AvoidBoth are incretin-based dual agonists targeting overlapping receptor systems. Combining would create redundant and potentially dangerous receptor overstimulation.
Survodutide
AvoidBoth are GLP-1/glucagon dual agonists with nearly identical mechanisms. No rationale for combination; risk of adverse effects from receptor overstimulation.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Pemvidutide
Related Peptides
5-Amino-1MQ
5-Amino-1-Methylquinolinium · NNMT Inhibitor
A small molecule NNMT inhibitor studied for metabolic effects in animal models. No human clinical trials have been conducted. Increases NAD+ levels in adipose tissue in preclinical studies.
Amycretin
NNC0487-0111 · Oral Amycretin · Subcutaneous Amycretin
A novel single-molecule dual GLP-1/amylin receptor agonist developed by Novo Nordisk. Unlike CagriSema (a fixed-dose combination), amycretin is a unified peptide that activates both pathways. Phase 1 trials showed superior weight loss signals versus semaglutide, with both oral and subcutaneous formulations in development.
AOD-9604
Anti-Obesity Drug 9604 · Tyr-hGH Fragment 177-191 · hGH Fragment 176-191
A modified fragment of human growth hormone (amino acids 176-191 with N-terminal tyrosine) studied for fat loss. Clinical development discontinued after Phase 2b/3 trials failed to show efficacy in 536 subjects. Now prohibited by WADA and excluded from FDA compounding.
Cagrilintide
AM833 · NN9838
A long-acting amylin analog developed by Novo Nordisk for weight management. Studied in Phase 3 trials as CagriSema (combination with semaglutide). The Phase 3 REDEFINE 1 trial showed -20.4% weight loss with cagrilintide-semaglutide versus -3.0% with placebo at 68 weeks.
CagriSema
Cagrilintide-Semaglutide · NNC0174-0833
A fixed-dose combination of cagrilintide (amylin analog) and semaglutide (GLP-1 agonist) for chronic weight management. Phase 3 REDEFINE trials demonstrate 20-23% weight loss at 68 weeks. NDA submitted to FDA December 2025. First GLP-1/amylin combination therapy.
CT-388
RG-6912
A dual GLP-1/GIP receptor agonist (INN enicepatide; also RO7795068) acquired by Roche through the $2.7 billion Carmot Therapeutics acquisition in 2024. The published Phase 1 trial (NCT04838405) showed 4.7-8.0% mean weight loss vs 0.5% placebo over 4 weeks; a more widely reported ~18.8% placebo-adjusted figure at 24 weeks comes from an unpublished Phase 1 extension reported via press release. Phase 2 obesity and T2D trials are completed or ongoing and Phase 3 began in 2026, positioning it as a competitive obesity therapeutic with a mechanism similar to tirzepatide.